(Q38888166)

7 September 2017

miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin (English)

1 reference

7 September 2017

1 reference

X Zhu

1

1 reference

7 September 2017

H Shen

2

1 reference

7 September 2017

X Yin

3

1 reference

7 September 2017

L Long

4

1 reference

7 September 2017

C Xie

5

1 reference

7 September 2017

Y Liu

6

1 reference

7 September 2017

L Hui

7

1 reference

7 September 2017

X Lin

8

1 reference

7 September 2017

Y Fang

9

1 reference

7 September 2017

Y Cao

10

1 reference

7 September 2017

Y Xu

11

1 reference

7 September 2017

M Li

12

1 reference

7 September 2017

W Xu

13

1 reference

7 September 2017

Y Li

14

1 reference

7 September 2017

language of work or name

English

0 references

publication date

13 April 2015

1 reference

7 September 2017

1 reference

7 September 2017

35

1 reference

7 September 2017

323-332

1 reference

7 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2015.84

7 September 2017

0 references

cites work

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Ovarian cancer: strategies for overcoming resistance to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Discrete molecular classes of ovarian cancer suggestive of unique mechanisms of transformation and metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Oncogenic roles of EMT-inducing transcription factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Twist is a potential oncogene that inhibits apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

EMT as the ultimate survival mechanism of cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Integrated genomic analyses of ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

miR-186, miR-3651 and miR-494: Potential biomarkers for oral squamous cell carcinoma extracted from whole blood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.84

31 March 2020

Identifiers

DOI

10.1038/ONC.2015.84

1 reference

Dimensions Publication ID

7 September 2017

0 references

1 reference